131896-42-9 Usage
Description
D-4-Thiazolylalanine is a non-proteinogenic amino acid, which means it is not one of the 20 standard amino acids used by cells in the biosynthesis of proteins. It is characterized by the presence of a thiazolyl group attached to the side chain of the alanine molecule. This unique structure makes it a valuable compound for various applications in scientific research and pharmaceutical development.
Uses
Used in Research and Development:
D-4-Thiazolylalanine is used as a chiral non-proteinogenic amino acid for various research purposes. Its distinct structure allows it to be employed in the study of enzyme specificity, protein folding, and the development of novel bioactive compounds. The compound can also be used to investigate the effects of non-proteinogenic amino acids on cellular processes and their potential role in the treatment of various diseases.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, D-4-Thiazolylalanine is used as a building block for the synthesis of new drugs and drug candidates. Its unique structure can be exploited to design molecules with specific biological activities, such as antimicrobial, antiviral, or anticancer properties. Additionally, the compound can be used to develop chiral drugs, which may exhibit improved efficacy and reduced side effects compared to their racemic counterparts.
Used in Enzyme Inhibition Studies:
D-4-Thiazolylalanine can be used as an inhibitor of specific enzymes, particularly those involved in the biosynthesis of proteins. By incorporating this non-proteinogenic amino acid into the active site of an enzyme, researchers can study the enzyme's mechanism of action and develop new strategies for inhibiting its activity. This can be particularly useful in the development of drugs targeting enzymes involved in disease processes.
Used in Drug Delivery Systems:
Similar to gallotannin, D-4-Thiazolylalanine can also be employed in the development of novel drug delivery systems. Its unique structure can be utilized to design carriers for targeted drug delivery, potentially improving the bioavailability and therapeutic outcomes of various drugs. This application can be particularly beneficial in the treatment of cancer, where targeted drug delivery can help minimize side effects and enhance the efficacy of chemotherapy.
Check Digit Verification of cas no
The CAS Registry Mumber 131896-42-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,1,8,9 and 6 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 131896-42:
(8*1)+(7*3)+(6*1)+(5*8)+(4*9)+(3*6)+(2*4)+(1*2)=139
139 % 10 = 9
So 131896-42-9 is a valid CAS Registry Number.
InChI:InChI=1/C6H8N2O2S/c1-4(6(9)10)8-5-2-11-3-7-5/h2-4,8H,1H3,(H,9,10)/t4-/m0/s1
131896-42-9Relevant articles and documents
-
Caldwell,Fox
, p. 2935 (1951)
-
Substituted quinoxaline-2-ones as glutamate receptor antagonists
-
, (2008/06/13)
A novel series of substituted quinoxaline 2-ones useful as neuroprotective agents are taught. Novel intermediates, processes of preparation, and pharmaceutical compositions containing the compounds are also taught. The compounds are glutamate receptor antagonists and are useful in the treatment of stroke, cerebral ischemia, or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, seizure disorders, pain, Alzheimer's, Parkinson's, and Huntington's Diseases.
Studies of unnatural amino acids and their peptides. II. The syntheses of DL-beta-(4-thiazolyl)-alpha-alanine and its peptides.
Watanabe,Kuwata,Sakata,Matsumura
, p. 2473 - 2476 (2007/10/04)
-
